Anti-inflammatory action of lipid nanocarrier-delivered myriocin

Therapeutic potential in cystic fibrosis

Anna Caretti, Alessandra Bragonzi, Marcella Facchini, Ida De Fino, Camilla Riva, Paolo Gasco, Claudia Musicanti, Josefina Casas, Gemma Fabriàs, Riccardo Ghidoni, Paola Signorelli

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Sphingolipids take part in immune response and can initiate and/or sustain inflammation. Various inflammatory diseases have been associated with increased ceramide content, and pharmacological reduction of ceramide diminishes inflammation damage in vivo. Inflammation and susceptibility to microbial infection are two elements in a vicious circle. Recently, sphingolipid metabolism inhibitors were used to reduce infection. Cystic fibrosis (CF) is characterized by a hyper-inflammation and an excessive innate immune response, which fails to evolve into adaptive immunity and to eradicate infection. Chronic infections result in lung damage and patient morbidity. Notably, ceramide content in mucosa airways is higher in CF mouse models and in patients than in control mice or healthy subjects. Methods: The therapeutic potential of myriocin, an inhibitor of the sphingolipid de novo synthesis rate limiting enzyme (Serine Palmitoyl Transferase, SPT),was investigated in CF cells and mice models. Results We treated CF human respiratory epithelial cells with myriocin, This treatment resulted in reduced basal, as well as TNFα-stimulated, inflammation. In turn, TNFα induced an increase in SPT in these cells, linking de novo synthesis of ceramide to inflammation. Furthermore, myriocin-loaded nanocarrier, injected intratrachea prior to P. aeruginosa challenge, enabled a significant reduction of lung infection and reduced inflammation. Conclusions: The presented data suggest that de novo ceramide synthesis is constitutively enhanced in CF mucosa and that it can be envisaged as pharmacological target for modulating inflammation and restoring effective innate immunity against acute infection. General significance Myriocin stands as a powerful immunomodulatory agent for inflammatory and infectious diseases.

Original languageEnglish
Pages (from-to)586-594
Number of pages9
JournalBBA - General Subjects
Volume1840
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Ceramides
Cystic Fibrosis
Anti-Inflammatory Agents
Sphingolipids
Inflammation
Lipids
Transferases
Infection
Serine
Therapeutics
Innate Immunity
Mucous Membrane
Metabolism
Pharmacology
Lung
thermozymocidin
Adaptive Immunity
Communicable Diseases
Enzymes
Healthy Volunteers

Keywords

  • Ceramide
  • Cystic fibrosis
  • Inflammation
  • Innate immune responses
  • Nanocarriers
  • Sphingolipids

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Anti-inflammatory action of lipid nanocarrier-delivered myriocin : Therapeutic potential in cystic fibrosis. / Caretti, Anna; Bragonzi, Alessandra; Facchini, Marcella; De Fino, Ida; Riva, Camilla; Gasco, Paolo; Musicanti, Claudia; Casas, Josefina; Fabriàs, Gemma; Ghidoni, Riccardo; Signorelli, Paola.

In: BBA - General Subjects, Vol. 1840, No. 1, 2014, p. 586-594.

Research output: Contribution to journalArticle

Caretti, A, Bragonzi, A, Facchini, M, De Fino, I, Riva, C, Gasco, P, Musicanti, C, Casas, J, Fabriàs, G, Ghidoni, R & Signorelli, P 2014, 'Anti-inflammatory action of lipid nanocarrier-delivered myriocin: Therapeutic potential in cystic fibrosis', BBA - General Subjects, vol. 1840, no. 1, pp. 586-594. https://doi.org/10.1016/j.bbagen.2013.10.018
Caretti, Anna ; Bragonzi, Alessandra ; Facchini, Marcella ; De Fino, Ida ; Riva, Camilla ; Gasco, Paolo ; Musicanti, Claudia ; Casas, Josefina ; Fabriàs, Gemma ; Ghidoni, Riccardo ; Signorelli, Paola. / Anti-inflammatory action of lipid nanocarrier-delivered myriocin : Therapeutic potential in cystic fibrosis. In: BBA - General Subjects. 2014 ; Vol. 1840, No. 1. pp. 586-594.
@article{ec278869259945ef85b81608d5da0da3,
title = "Anti-inflammatory action of lipid nanocarrier-delivered myriocin: Therapeutic potential in cystic fibrosis",
abstract = "Background: Sphingolipids take part in immune response and can initiate and/or sustain inflammation. Various inflammatory diseases have been associated with increased ceramide content, and pharmacological reduction of ceramide diminishes inflammation damage in vivo. Inflammation and susceptibility to microbial infection are two elements in a vicious circle. Recently, sphingolipid metabolism inhibitors were used to reduce infection. Cystic fibrosis (CF) is characterized by a hyper-inflammation and an excessive innate immune response, which fails to evolve into adaptive immunity and to eradicate infection. Chronic infections result in lung damage and patient morbidity. Notably, ceramide content in mucosa airways is higher in CF mouse models and in patients than in control mice or healthy subjects. Methods: The therapeutic potential of myriocin, an inhibitor of the sphingolipid de novo synthesis rate limiting enzyme (Serine Palmitoyl Transferase, SPT),was investigated in CF cells and mice models. Results We treated CF human respiratory epithelial cells with myriocin, This treatment resulted in reduced basal, as well as TNFα-stimulated, inflammation. In turn, TNFα induced an increase in SPT in these cells, linking de novo synthesis of ceramide to inflammation. Furthermore, myriocin-loaded nanocarrier, injected intratrachea prior to P. aeruginosa challenge, enabled a significant reduction of lung infection and reduced inflammation. Conclusions: The presented data suggest that de novo ceramide synthesis is constitutively enhanced in CF mucosa and that it can be envisaged as pharmacological target for modulating inflammation and restoring effective innate immunity against acute infection. General significance Myriocin stands as a powerful immunomodulatory agent for inflammatory and infectious diseases.",
keywords = "Ceramide, Cystic fibrosis, Inflammation, Innate immune responses, Nanocarriers, Sphingolipids",
author = "Anna Caretti and Alessandra Bragonzi and Marcella Facchini and {De Fino}, Ida and Camilla Riva and Paolo Gasco and Claudia Musicanti and Josefina Casas and Gemma Fabri{\`a}s and Riccardo Ghidoni and Paola Signorelli",
year = "2014",
doi = "10.1016/j.bbagen.2013.10.018",
language = "English",
volume = "1840",
pages = "586--594",
journal = "Biochimica et Biophysica Acta - General Subjects",
issn = "0304-4165",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Anti-inflammatory action of lipid nanocarrier-delivered myriocin

T2 - Therapeutic potential in cystic fibrosis

AU - Caretti, Anna

AU - Bragonzi, Alessandra

AU - Facchini, Marcella

AU - De Fino, Ida

AU - Riva, Camilla

AU - Gasco, Paolo

AU - Musicanti, Claudia

AU - Casas, Josefina

AU - Fabriàs, Gemma

AU - Ghidoni, Riccardo

AU - Signorelli, Paola

PY - 2014

Y1 - 2014

N2 - Background: Sphingolipids take part in immune response and can initiate and/or sustain inflammation. Various inflammatory diseases have been associated with increased ceramide content, and pharmacological reduction of ceramide diminishes inflammation damage in vivo. Inflammation and susceptibility to microbial infection are two elements in a vicious circle. Recently, sphingolipid metabolism inhibitors were used to reduce infection. Cystic fibrosis (CF) is characterized by a hyper-inflammation and an excessive innate immune response, which fails to evolve into adaptive immunity and to eradicate infection. Chronic infections result in lung damage and patient morbidity. Notably, ceramide content in mucosa airways is higher in CF mouse models and in patients than in control mice or healthy subjects. Methods: The therapeutic potential of myriocin, an inhibitor of the sphingolipid de novo synthesis rate limiting enzyme (Serine Palmitoyl Transferase, SPT),was investigated in CF cells and mice models. Results We treated CF human respiratory epithelial cells with myriocin, This treatment resulted in reduced basal, as well as TNFα-stimulated, inflammation. In turn, TNFα induced an increase in SPT in these cells, linking de novo synthesis of ceramide to inflammation. Furthermore, myriocin-loaded nanocarrier, injected intratrachea prior to P. aeruginosa challenge, enabled a significant reduction of lung infection and reduced inflammation. Conclusions: The presented data suggest that de novo ceramide synthesis is constitutively enhanced in CF mucosa and that it can be envisaged as pharmacological target for modulating inflammation and restoring effective innate immunity against acute infection. General significance Myriocin stands as a powerful immunomodulatory agent for inflammatory and infectious diseases.

AB - Background: Sphingolipids take part in immune response and can initiate and/or sustain inflammation. Various inflammatory diseases have been associated with increased ceramide content, and pharmacological reduction of ceramide diminishes inflammation damage in vivo. Inflammation and susceptibility to microbial infection are two elements in a vicious circle. Recently, sphingolipid metabolism inhibitors were used to reduce infection. Cystic fibrosis (CF) is characterized by a hyper-inflammation and an excessive innate immune response, which fails to evolve into adaptive immunity and to eradicate infection. Chronic infections result in lung damage and patient morbidity. Notably, ceramide content in mucosa airways is higher in CF mouse models and in patients than in control mice or healthy subjects. Methods: The therapeutic potential of myriocin, an inhibitor of the sphingolipid de novo synthesis rate limiting enzyme (Serine Palmitoyl Transferase, SPT),was investigated in CF cells and mice models. Results We treated CF human respiratory epithelial cells with myriocin, This treatment resulted in reduced basal, as well as TNFα-stimulated, inflammation. In turn, TNFα induced an increase in SPT in these cells, linking de novo synthesis of ceramide to inflammation. Furthermore, myriocin-loaded nanocarrier, injected intratrachea prior to P. aeruginosa challenge, enabled a significant reduction of lung infection and reduced inflammation. Conclusions: The presented data suggest that de novo ceramide synthesis is constitutively enhanced in CF mucosa and that it can be envisaged as pharmacological target for modulating inflammation and restoring effective innate immunity against acute infection. General significance Myriocin stands as a powerful immunomodulatory agent for inflammatory and infectious diseases.

KW - Ceramide

KW - Cystic fibrosis

KW - Inflammation

KW - Innate immune responses

KW - Nanocarriers

KW - Sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=84887039493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887039493&partnerID=8YFLogxK

U2 - 10.1016/j.bbagen.2013.10.018

DO - 10.1016/j.bbagen.2013.10.018

M3 - Article

VL - 1840

SP - 586

EP - 594

JO - Biochimica et Biophysica Acta - General Subjects

JF - Biochimica et Biophysica Acta - General Subjects

SN - 0304-4165

IS - 1

ER -